II 

110TH CONGRESS 

1ST SESSION S. 742 

To amend the Toxic Substances Control Act to reduce the health risks 

posed by asbestos-containing products, and for other purposes. 

IN THE SENATE OF THE UNITED STATES 

MARCH 1, 2007 

Mrs. MURRAY (for herself, Mrs. BOXER, Mr. BAUCUS, Mr. BROWN, Mrs. 

CLINTON, Mr. DURBIN, Mr. FEINGOLD, Mrs. FEINSTEIN, Mr. HARKIN, 

Mr. KENNEDY, Mr. KERRY, Mr. LEAHY, and Mr. REID) introduced the 

following bill; which was read twice and referred to the Committee on Environment and Public Works 

A BILL 

To amend the Toxic Substances Control Act to reduce the 

health risks posed by asbestos-containing products, and 

for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Ban Asbestos in Amer5 ica Act of 2007’’. 

6 SEC. 2. FINDINGS. 

7 Congress finds that— 


pwalker on PROD1PC71 with BILLS
2 

•S 742 IS

1 (1)(A) the Administrator of the Environmental 

2 Protection Agency has classified asbestos as a cat3 egory A human carcinogen, the highest cancer haz4 ard classification for a substance; and 

5 (B) the International Agency for Research on 

6 Cancer has classified asbestos as a class 1 human 

7 carcinogen; 

8 (2) many people in the United States incor9 rectly believe that— 

10 (A) asbestos has been banned in the 

11 United States; and 

12 (B) there is no risk of exposure to asbestos 

13 through the use of new commercial products; 

14 (3) the United States Geological Survey re15 ported that, in 2006, the United States used 2,000 

16 metric tons of asbestos, of which approximately— 

17 (A) 55 percent was used in roofing prod18 ucts; 

19 (B) 26 percent was used in coatings; and 

20 (C) 19 percent was used in other products, 

21 such as friction products; 

22 (4) the Department of Commerce estimates 

23 that the United States imports more than 

24 $100,000,000 of brake parts per year; 

25 (5) available evidence suggests that— 


pwalker on PROD1PC71 with BILLS
3 

•S 742 IS

1 (A) imports of some types of asbestos-con2 taining products are increasing; and 

3 (B) some of those products are imported 

4 from foreign countries in which asbestos is 

5 poorly regulated; 

6 (6) there is no known safe level of exposure to 

7 asbestos; 

8 (7) even low levels of exposure to asbestos may 

9 cause asbestos-related diseases, including mesothe10 lioma; 

11 (8) millions of workers in the United States 

12 have been, and continue to be, exposed to dangerous 

13 levels of asbestos; 

14 (9) worker deaths from noncancerous lung dis15 ease can occur at levels of exposure to asbestos 

16 below the levels allowed by the Occupational Safety 

17 and Health Administration as of the date of enact18 ment of this Act; 

19 (10) families of workers are put at risk because 

20 of asbestos brought home by the workers on the 

21 shoes, clothes, skin, and hair of the workers; 

(11) approximately 1 22 ⁄3 of mesothelioma victims 

23 were exposed to asbestos while serving the United 

24 States on Navy ships or shipyards; 


pwalker on PROD1PC71 with BILLS
4 

•S 742 IS

1 (12) the National Institutes of Health reported 

2 to Congress in 2006 that mesothelioma is a difficult 

3 disease to detect, diagnose, and treat; 

4 (13) the Environmental Working Group esti5 mates that as many as 10,000 citizens of the United 

6 States die each year from mesothelioma and other 

7 asbestos-related diseases; 

8 (14)(A) mesothelioma responds poorly to con9 ventional chemotherapy; and 

10 (B) although new combination treatments for 

11 mesothelioma have demonstrated some benefits— 

12 (i) the median survival period for mesothe13 lioma is only 1 year after diagnosis of the dis14 ease; and 

15 (ii) the majority of mesothelioma patients 

16 die within 2 years of diagnosis of the disease; 

17 (15) in hearings before Congress in the early 

18 1970s, the example of asbestos was used to justify 

19 the need for comprehensive legislation on toxic sub20 stances; 

21 (16) in 1976, Congress passed the Toxic Sub22 stances Control Act (15 U.S.C. 2601 et seq.); 

23 (17) in 1989, the Administrator promulgated 

24 final regulations under title II of the Toxic SubVerDate Aug 31 2005 20:50 Mar 03, 2007 Jkt 059200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6201 E:\BILLS\S742.IS S742

pwalker on PROD1PC71 with BILLS
5 

•S 742 IS

1 stances Control Act (15 U.S.C. 2641 et seq.) to 

2 phase out asbestos in consumer products by 1997; 

3 (18) in 1991, the United States Court of Ap4 peals for the 5th Circuit overturned portions of the 

5 regulations, and the Federal Government did not ap6 peal the decision to the Supreme Court; 

7 (19) as a result, while new applications for as8 bestos were banned, asbestos is still being imported 

9 and used in some consumer and industrial products 

10 in the United States; 

11 (20) the National Cancer Institute recognizes a 

12 clear need for new agents to improve the outlook for 

13 patients with mesothelioma and other asbestos-re14 lated diseases; 

15 (21) the National Institutes of Health should 

16 continue to improve detection, treatment, and man17 agement of asbestos-related diseases, such as meso18 thelioma, including by providing continued support 

19 for the pleural mesothelioma treatment and research 

20 program and peritoneal surgical initiatives; 

21 (22) given the risk of asbestos exposure for 

22 members and veterans of the Armed Forces, the De23 partment of Defense has an obligation to study dis24 eases related to asbestos exposure in the military 

25 and veteran population, including by conducting reVerDate Aug 31 2005 20:50 Mar 03, 2007 Jkt 059200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6201 E:\BILLS\S742.IS S742

pwalker on PROD1PC71 with BILLS
6 

•S 742 IS

1 search in coordination with the National Institutes 

2 of Health on the early detection and treatment of 

3 mesothelioma; 

4 (23) asbestos has been banned in 40 countries, 

5 including Argentina, Australia, Austria, Belgium, 

6 Chile, Croatia, the Czech Republic, Denmark, Esto7 nia, Finland, France, Germany, Iceland, Ireland, 

8 Italy, Japan, Latvia, Luxembourg, the Netherlands, 

9 Norway, Poland, Portugal, Saudi Arabia, the Slovak 

10 Republic, Spain, Sweden, Switzerland, and the 

11 United Kingdom; 

12 (24) asbestos was banned throughout the Euro13 pean Union in 2005; and 

14 (25) banning asbestos from being used in or 

15 imported into the United States will provide cer16 tainty to manufacturers, builders, environmental re17 mediation firms, workers, and consumers that after 

18 a specific date, asbestos will not be used or added 

19 to new construction and manufacturing materials 

20 used in this country. 

21 SEC. 3. ASBESTOS-CONTAINING PRODUCTS. 

22 (a) IN GENERAL.—Title II of the Toxic Substances 

23 Control Act (15 U.S.C. 2641 et seq.) is amended— 

24 (1) by inserting before section 201 (15 U.S.C. 

25 2641) the following: 


pwalker on PROD1PC71 with BILLS
7 

•S 742 IS

1 ‘‘Subtitle A—General Provisions’’; 

2 and 

3 (2) by adding at the end the following: 

4 ‘‘Subtitle B—Asbestos-Containing 

5 Products 

6 ‘‘SEC. 221. DEFINITIONS. 

7 ‘‘In this subtitle: 

8 ‘‘(1) ASBESTOS-CONTAINING PRODUCT.—The 

9 term ‘asbestos-containing product’ means any prod10 uct (including any part) to which asbestos is delib11 erately or knowingly added or in which asbestos is 

12 deliberately or knowingly used in any concentration. 

13 ‘‘(2) BIOPERSISTENT DURABLE FIBER.— 

14 ‘‘(A) IN GENERAL.—The term ‘bioper15 sistent durable fiber’ means a silicate fiber 

16 that— 

17 ‘‘(i) occurs naturally in the environ18 ment; and 

19 ‘‘(ii) is similar to asbestos in— 

20 ‘‘(I) resistance to dissolution; 

21 ‘‘(II) leaching; and 

22 ‘‘(III) other physical, chemical, 

23 or biological processes expected from 

24 contact with lung cells and other cells 

25 and fluids in the human body. 


pwalker on PROD1PC71 with BILLS
8 

•S 742 IS

1 ‘‘(B) INCLUSIONS.—The term ‘bioper2 sistent durable fiber’ includes— 

3 ‘‘(i) richterite; 

4 ‘‘(ii) winchite; 

5 ‘‘(iii) erionite; and 

6 ‘‘(iv) non-asbestiform varieties of 

7 amosite, crocidolite, anthophyllite, 

8 tremolite, and actinolite. 

9 ‘‘(3) CONTAMINANT-ASBESTOS PRODUCT.—The 

10 term ‘contaminant-asbestos product’ means any 

11 product that contains asbestos as a contaminant of 

12 any mineral or other substance, in any concentra13 tion. 

14 ‘‘(4) DISTRIBUTE IN COMMERCE.— 

15 ‘‘(A) IN GENERAL.—The term ‘distribute 

16 in commerce’ has the meaning given the term 

17 in section 3. 

18 ‘‘(B) EXCLUSIONS.—The term ‘distribute 

19 in commerce’ does not include— 

20 ‘‘(i) an action taken with respect to 

21 an asbestos-containing product in connec22 tion with the end use of the asbestos-con23 taining product by a person that is an end 

24 user; or 


pwalker on PROD1PC71 with BILLS
9 

•S 742 IS

1 ‘‘(ii) distribution of an asbestos-con2 taining product by a person solely for the 

3 purpose of disposal of the asbestos-con4 taining product in compliance with applica5 ble Federal, State, and local requirements. 

6 ‘‘(5) FIBER.—The term ‘fiber’ means an acic7 ular single crystal or similarly elongated 

8 polycrystalline aggregate particle with a length to 

9 width ratio of 3 to 1 or greater. 

10 ‘‘(6) PERSON.—The term ‘person’ means— 

11 ‘‘(A) any individual; 

12 ‘‘(B) any corporation, company, associa13 tion, firm, partnership, joint venture, sole pro14 prietorship, or other for-profit or nonprofit 

15 business entity (including any manufacturer, 

16 importer, distributor, or processor); 

17 ‘‘(C) any Federal, State, or local depart18 ment, agency, or instrumentality; and 

19 ‘‘(D) any interstate body. 

20 ‘‘SEC. 222. NATIONAL INSTITUTE FOR OCCUPATIONAL 

21 SAFETY AND HEALTH STUDY. 

22 ‘‘(a) IN GENERAL.—The National Institute for Occu23 pational Safety and Health shall conduct a study and, not 

24 later than 18 months after the date of enactment of this 

25 subtitle, submit to the Administrator, the Committees on 


pwalker on PROD1PC71 with BILLS
10 

•S 742 IS

1 Environment and Public Works and Health, Education, 

2 Labor, and Pensions of the Senate, and other Federal 

3 agencies, as appropriate, a report containing— 

4 ‘‘(1) a description of the current state of the 

5 science relating to— 

6 ‘‘(A) the disease mechanisms and health 

7 effects of exposure to asbestos and other bioper8 sistent durable fibers; and 

9 ‘‘(B) methods for measuring and analyzing 

10 asbestos; 

11 ‘‘(2) a description of the current status of label12 ing practices relating to asbestos-containing mate13 rial; and 

14 ‘‘(3) recommendations for future asbestos-re15 lated disease research and exposure assessment 

16 practice needs. 

17 ‘‘(b) AUTHORIZATION OF APPROPRIATIONS.—There 

18 are authorized to be appropriated such sums as are nec19 essary to carry out this section. 

20 ‘‘SEC. 223. PROHIBITION ON ASBESTOS-CONTAINING PROD21 UCTS. 

22 ‘‘(a) IN GENERAL.—Subject to subsection (b), the 

23 Administrator shall promulgate— 

24 ‘‘(1) not later than 1 year after the date of en25 actment of this subtitle, proposed regulations that— 


pwalker on PROD1PC71 with BILLS
11 

•S 742 IS

1 ‘‘(A) prohibit persons from importing, 

2 manufacturing, processing, or distributing in 

3 commerce asbestos-containing products; and 

4 ‘‘(B) provide for implementation of sub5 sections (b) and (c); and 

6 ‘‘(2) not later than 2 years after the date of en7 actment of this subtitle, final regulations that, effec8 tive beginning 60 days after the date of promulga9 tion, prohibit persons from importing, manufac10 turing, processing, or distributing in commerce as11 bestos-containing products. 

12 ‘‘(b) EXEMPTIONS.— 

13 ‘‘(1) IN GENERAL.—Any person may petition 

14 the Administrator for, and the Administrator may 

15 grant, an exemption from the requirements of sub16 section (a) if the Administrator determines that— 

17 ‘‘(A) the exemption would not result in an 

18 unreasonable risk of injury to public health or 

19 the environment; and 

20 ‘‘(B) the person has made good faith ef21 forts to develop, but has been unable to develop, 

22 a substance, or identify a mineral, that— 

23 ‘‘(i) does not present an unreasonable 

24 risk of injury to public health or the envi25 ronment; and 


pwalker on PROD1PC71 with BILLS
12 

•S 742 IS

1 ‘‘(ii) may be substituted for an asbes2 tos-containing product. 

3 ‘‘(2) TERMS AND CONDITIONS.—An exemption 

4 granted under this subsection shall be in effect for 

5 such period (not to exceed 1 year) and subject to 

6 such terms and conditions as the Administrator may 

7 prescribe. 

8 ‘‘(3) GOVERNMENTAL USE.—The Administrator 

9 shall provide an exemption from the requirements of 

10 subsection (a), without review or limit on duration, 

11 if the exemption for an asbestos-containing product 

12 is— 

13 ‘‘(A) sought by the Secretary of Defense 

14 and the Secretary certifies, and provides a copy 

15 of that certification to Congress, that— 

16 ‘‘(i) use of the asbestos containing 

17 product is necessary to the critical func18 tions of the Department; 

19 ‘‘(ii) no reasonable alternatives to the 

20 asbestos containing product exist for the 

21 intended purpose; and 

22 ‘‘(iii) use of the asbestos containing 

23 product will not result in an unreasonable 

24 risk to health or the environment; or 


pwalker on PROD1PC71 with BILLS
13 

•S 742 IS

1 ‘‘(B) sought by the Administrator of the 

2 National Aeronautics and Space Administration 

3 and the Administrator of the National Aero4 nautics and Space Administration certifies, and 

5 provides a copy of that certification to Con6 gress, that— 

7 ‘‘(i) the asbestos-containing product is 

8 necessary to the critical functions of the 

9 National Aeronautics and Space Adminis10 tration; 

11 ‘‘(ii) no reasonable alternatives to the 

12 asbestos-containing product exist for the 

13 intended purpose; and 

14 ‘‘(iii) the use of the asbestos-con15 taining product will not result in an unrea16 sonable risk to health or the environment. 

17 ‘‘(c) DISPOSAL.— 

18 ‘‘(1) IN GENERAL.—Except as provided in para19 graph (2), not later than 2 years after the date of 

20 enactment of this subtitle, each person that pos21 sesses an asbestos-containing product that is subject 

22 to the prohibition established under this section shall 

23 dispose of the asbestos-containing product, by a 

24 means that is in compliance with applicable Federal, 

25 State, and local requirements. 


pwalker on PROD1PC71 with BILLS
14 

•S 742 IS

1 ‘‘(2) EXEMPTION.—Nothing in paragraph (1)— 

2 ‘‘(A) applies to an asbestos-containing 

3 product that— 

4 ‘‘(i) is no longer in the stream of com5 merce; or 

6 ‘‘(ii) is in the possession of an end 

7 user; or 

8 ‘‘(B) requires that an asbestos-containing 

9 product described in subparagraph (A) be re10 moved or replaced. 

11 ‘‘SEC. 224. PUBLIC EDUCATION PROGRAM. 

12 ‘‘(a) IN GENERAL.—Not later than 1 year after the 

13 date of enactment of this subtitle, the Administrator, in 

14 consultation with the Chairman of the Consumer Product 

15 Safety Commission, the Director of the Centers for Dis16 ease Control and Prevention, and the Secretary of Labor, 

17 shall establish a plan— 

18 ‘‘(1) to increase awareness of the dangers posed 

19 by— 

20 ‘‘(A) asbestos-containing products and con21 taminants in homes and workplaces; and 

22 ‘‘(B) asbestos-related diseases; 

23 ‘‘(2) to provide current and comprehensive in24 formation to asbestos-related disease patients, family 


pwalker on PROD1PC71 with BILLS
15 

•S 742 IS

1 members of patients, and front-line health care pro2 viders on— 

3 ‘‘(A) the dangers of asbestos exposure; 

4 ‘‘(B) asbestos-related labeling information; 

5 ‘‘(C) health effects of exposure to asbestos; 

6 ‘‘(D) symptoms of asbestos exposure; and 

7 ‘‘(E) available and developing treatments 

8 for asbestos-related diseases, including clinical 

9 trials; 

10 ‘‘(3) to encourage asbestos-related disease pa11 tients, family members of patients, and front-line 

12 health care providers to participate in research and 

13 treatment endeavors relating to asbestos; and 

14 ‘‘(4) to encourage health care providers and re15 searchers to provide to asbestos-related disease pa16 tients and family members of patients information 

17 relating to research, diagnostic, and clinical treat18 ments relating to asbestos. 

19 ‘‘(b) GREATEST RISKS.—In establishing the pro20 gram, the Administrator shall give priority to asbestos21 containing products and contaminant-asbestos products 

22 used by consumers and workers that pose the greatest risk 

23 of injury to human health. 


pwalker on PROD1PC71 with BILLS
16 

•S 742 IS

1 ‘‘(c) AUTHORIZATION OF APPROPRIATIONS.—There 

2 are authorized to be appropriated such sums as are nec3 essary to carry out this section.’’. 

4 (b) CONFORMING AMENDMENT.—The table of con5 tents in sections 1 of the Toxic Substances Control Act 

6 (15 U.S.C. prec. 2601) is amended— 

7 (1) by inserting before the item relating to sec8 tion 201 the following: 

‘‘Subtitle A–General Provisions’’; 

9 and 

10 (2) by adding at the end of the items relating 

11 to title II the following: 

‘‘Subtitle B—Asbestos-Containing Products 

‘‘Sec. 221. Definitions. 

‘‘Sec. 222. National Institute for Occupational Safety and Health study. 

‘‘Sec. 223. Prohibition on asbestos-containing products. 

‘‘Sec. 224. Public education program.’’. 

12 SEC. 4. ASBESTOS-RELATED DISEASES. 

13 (a) IN GENERAL.—Subpart 1 of part C of title IV 

14 of the Public Health Service Act (42 U.S.C. 285 et seq.) 

15 is amended by adding at the end the following: 

16 ‘‘SEC. 417E. RESEARCH ON ASBESTOS-RELATED DISEASES. 

17 ‘‘(a) IN GENERAL.—The Secretary, acting through 

18 the Director of NIH and the Director of the Centers for 

19 Disease Control and Prevention, shall expand, intensify, 

20 and coordinate programs for the conduct and support of 

21 research on diseases caused by exposure to asbestos, par22 ticularly mesothelioma, asbestosis, and pleural injuries. 


pwalker on PROD1PC71 with BILLS
17 

•S 742 IS

1 ‘‘(b) ADMINISTRATION.—The Secretary shall carry 

2 out this section in collaboration with— 

3 ‘‘(1) the Administrator of the Agency for Toxic 

4 Substances and Disease Registry; 

5 ‘‘(2) the Director of the National Institute for 

6 Occupational Safety and Health; and 

7 ‘‘(3) the head of any other agency, as the Sec8 retary determines to be appropriate. 

9 ‘‘(c) ASBESTOS-RELATED DISEASE REGISTRY.— 

10 ‘‘(1) IN GENERAL.—Not later than 1 year after 

11 the date of enactment of this section, the Director 

12 of the Centers for Disease Control and Prevention, 

13 in cooperation with the Director of the National In14 stitute for Occupational Safety and Health and the 

15 Administrator of the Agency for Toxic Substances 

16 and Disease Registry, shall establish a mechanism 

17 by which to obtain, coordinate, and provide data and 

18 specimens from— 

19 ‘‘(A) State cancer registries and other can20 cer registries; 

21 ‘‘(B) the National Mesothelioma Virtual 

22 Registry and Tissue Bank; and 

23 ‘‘(C) each entity participating in the asbes24 tos-related disease research and treatment net25 work established under section 417F(a). 


pwalker on PROD1PC71 with BILLS
18 

•S 742 IS

1 ‘‘(2) TREATMENT.—The data and specimens 

2 described in paragraph (1) shall form the basis for 

3 establishing a national clearinghouse for data and 

4 specimens relating to asbestos-related diseases, with 

5 a particular emphasis on mesothelioma. 

6 ‘‘(d) AUTHORIZATION OF APPROPRIATIONS.—In ad7 dition to amounts made available for the purposes de8 scribed in subsection (a) under other law, there are au9 thorized to be appropriated to carry out this section such 

10 sums as are necessary for fiscal year 2008 and each fiscal 

11 year thereafter. 

12 ‘‘SEC. 417F. ASBESTOS-RELATED DISEASE RESEARCH AND 

13 TREATMENT NETWORK. 

14 ‘‘(a) ESTABLISHMENT.—For each of fiscal years 

15 2008 through 2012, the Director of NIH, in collaboration 

16 with other applicable Federal, State, and local agencies 

17 and departments, shall establish and maintain an asbes18 tos-related disease research and treatment network (re19 ferred to in this section as the ‘Network’) to support the 

20 detection, prevention, treatment, and cure of asbestos-re21 lated diseases, with particular emphasis on malignant 

22 mesothelioma. 

23 ‘‘(b) INCLUSIONS.—The Network shall include— 

24 ‘‘(1) intramural research initiatives of the Na25 tional Institutes of Health; and 


pwalker on PROD1PC71 with BILLS
19 

•S 742 IS

1 ‘‘(2) at least 10 extramural asbestos-related dis2 ease research and treatment centers, as selected by 

3 the Director of NIH in accordance with subsection 

4 (c). 

5 ‘‘(c) EXTRAMURAL ASBESTOS-RELATED DISEASE

6 RESEARCH AND TREATMENT CENTERS.— 

7 ‘‘(1) IN GENERAL.—For each fiscal year during 

8 which the Network is operated and maintained 

9 under subsection (a), the Director of NIH shall se10 lect for inclusion in the Network not less than 10 

11 nonprofit hospitals, universities, or medical or re12 search institutions incorporated or organized in the 

13 United States that, as determined by the Director of 

14 NIH— 

15 ‘‘(A) have exemplary experience and quali16 fications in research and treatment of asbestos17 related diseases; 

18 ‘‘(B) have access to an appropriate popu19 lation of patients with asbestos-related diseases; 

20 and 

21 ‘‘(C) are geographically distributed 

22 throughout the United States, with special con23 sideration given to areas of high incidence of 

24 asbestos-related diseases. 


pwalker on PROD1PC71 with BILLS
20 

•S 742 IS

1 ‘‘(2) REQUIREMENTS.—Each center selected 

2 under paragraph (1) shall— 

3 ‘‘(A) be chosen by the Director of NIH 

4 after competitive peer review; 

5 ‘‘(B) conduct laboratory and clinical re6 search, including clinical trials, relating to— 

7 ‘‘(i) mechanisms for effective thera8 peutic treatment of asbestos-related dis9 eases; 

10 ‘‘(ii) early detection and prevention of 

11 asbestos-related diseases; 

12 ‘‘(iii) palliation of asbestos-related dis13 ease symptoms; and 

14 ‘‘(iv) pain management with respect 

15 to asbestos-related diseases; 

16 ‘‘(C) offer to asbestos-related disease pa17 tients travel and lodging assistance as nec18 essary— 

19 ‘‘(i) to accommodate the maximum 

20 number of patients practicable; and 

21 ‘‘(ii) to serve a number of patients at 

22 the center sufficient to conduct a meaning23 ful clinical trial; 

24 ‘‘(D) seek to collaborate with at least 1 

25 medical center of the Department of Veterans 


pwalker on PROD1PC71 with BILLS
21 

•S 742 IS

1 Affairs to provide research benefits and care to 

2 veterans who have suffered excessively from as3 bestos-related diseases, particularly mesothe4 lioma; and 

5 ‘‘(E) coordinate the research and treat6 ment efforts of the center (including specimen 

7 sharing and use of common infomatics) with 

8 other entities included in— 

9 ‘‘(i) the Network; and 

10 ‘‘(ii) the National Virtual Mesothe11 lioma Registry and Tissue Bank. 

12 ‘‘(3) PERIOD OF INCLUSION.—A center selected 

13 by the Director of NIH under this subsection shall 

14 be included in the Network for— 

15 ‘‘(A) the 1-year period beginning on the 

16 date of selection of the center; or 

17 ‘‘(B) such longer period as the Director of 

18 NIH determines to be appropriate. 

19 ‘‘(d) GRANTS.—The Director of NIH shall provide to 

20 each center selected for inclusion in the Network under 

21 subsection (c) for the fiscal year a grant in an amount 

22 equal to $1,000,000 to support the detection, prevention, 

23 treatment, and cure of asbestos-related diseases, with par24 ticular emphasis on malignant mesothelioma. 


pwalker on PROD1PC71 with BILLS
22 

•S 742 IS

1 ‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There 

2 is authorized to be appropriated to carry out this section 

3 $10,000,000 for each of fiscal years 2008 through 2012. 

4 ‘‘SEC. 417G. DEPARTMENT OF DEFENSE RESEARCH. 

5 ‘‘(a) IN GENERAL.—The Secretary, acting through 

6 the United States Army Medical Research and Materiel 

7 Command, shall support research on mesothelioma and 

8 other asbestos-related diseases that has clear scientific 

9 value and direct relevance to the health of members and 

10 veterans of the Armed Forces, in accordance with the ap11 propriate congressionally directed medical research pro12 gram, with the goal of advancing the understanding, early 

13 detection, and treatment of asbestos-related mesothelioma 

14 and other asbestos-related diseases. 

15 ‘‘(b) ADMINISTRATION.—The Secretary shall carry 

16 out this section in collaboration with— 

17 ‘‘(1) the Director of NIH; 

18 ‘‘(2) the Director of the National Institute of 

19 Occupational Safety and Health; and 

20 ‘‘(3) the head of any other agency, as the Sec21 retary determines to be appropriate. 

22 ‘‘(c) AUTHORIZATION OF APPROPRIATIONS.—There 

23 are authorized to be appropriated to carry out this section 


pwalker on PROD1PC71 with BILLS
23 

•S 742 IS

1 such sums as are necessary for fiscal year 2008 and each 

2 fiscal year thereafter.’’. 

Æ 


pwalker on PROD1PC71 with BILLS